146 related articles for article (PubMed ID: 22353489)
1. Co-amorphous simvastatin and glipizide combinations show improved physical stability without evidence of intermolecular interactions.
Löbmann K; Strachan C; Grohganz H; Rades T; Korhonen O; Laitinen R
Eur J Pharm Biopharm; 2012 May; 81(1):159-69. PubMed ID: 22353489
[TBL] [Abstract][Full Text] [Related]
2. Stable amorphous binary systems of glipizide and atorvastatin powders with enhanced dissolution profiles: formulation and characterization.
Renuka ; Singh SK; Gulati M; Narang R
Pharm Dev Technol; 2017 Feb; 22(1):13-25. PubMed ID: 26708555
[TBL] [Abstract][Full Text] [Related]
3. Enhanced dissolution rate and synchronized release of drugs in binary systems through formulation: Amorphous naproxen-cimetidine mixtures prepared by mechanical activation.
Allesø M; Chieng N; Rehder S; Rantanen J; Rades T; Aaltonen J
J Control Release; 2009 May; 136(1):45-53. PubMed ID: 19331842
[TBL] [Abstract][Full Text] [Related]
4. Characterization of Amorphous and Co-Amorphous Simvastatin Formulations Prepared by Spray Drying.
Craye G; Löbmann K; Grohganz H; Rades T; Laitinen R
Molecules; 2015 Dec; 20(12):21532-48. PubMed ID: 26633346
[TBL] [Abstract][Full Text] [Related]
5. Amino acids as co-amorphous excipients for simvastatin and glibenclamide: physical properties and stability.
Laitinen R; Löbmann K; Grohganz H; Strachan C; Rades T
Mol Pharm; 2014 Jul; 11(7):2381-9. PubMed ID: 24852326
[TBL] [Abstract][Full Text] [Related]
6. [The development of co-amorphous drug systems].
Yao J; Shi NQ; Wang XL
Yao Xue Xue Bao; 2013 May; 48(5):648-54. PubMed ID: 23888685
[TBL] [Abstract][Full Text] [Related]
7. Co-Amorphous Simvastatin-Nifedipine with Enhanced Solubility for Possible Use in Combination Therapy of Hypertension and Hypercholesterolemia.
Martínez-Jiménez C; Cruz-Angeles J; Videa M; Martínez LM
Molecules; 2018 Aug; 23(9):. PubMed ID: 30154310
[TBL] [Abstract][Full Text] [Related]
8. Influence of particle size and preparation methods on the physical and chemical stability of amorphous simvastatin.
Zhang F; Aaltonen J; Tian F; Saville DJ; Rades T
Eur J Pharm Biopharm; 2009 Jan; 71(1):64-70. PubMed ID: 18703139
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo studies on the complexes of glipizide with water-soluble β-cyclodextrin-epichlorohydrin polymers.
Nie S; Zhang S; Pan W; Liu Y
Drug Dev Ind Pharm; 2011 May; 37(5):606-12. PubMed ID: 21469949
[TBL] [Abstract][Full Text] [Related]
10. A comparison of spray drying and milling in the production of amorphous dispersions of sulfathiazole/polyvinylpyrrolidone and sulfadimidine/polyvinylpyrrolidone.
Caron V; Tajber L; Corrigan OI; Healy AM
Mol Pharm; 2011 Apr; 8(2):532-42. PubMed ID: 21323367
[TBL] [Abstract][Full Text] [Related]
11. Development of a robust once-a-day glipizide matrix system.
Jamzad S; Fassihi R
J Pharm Pharmacol; 2007 Jun; 59(6):769-75. PubMed ID: 17637169
[TBL] [Abstract][Full Text] [Related]
12. Microwave-induced solid dispersion technology to improve bioavailability of glipizide.
Isaac J; Kaity S; Ganguly S; Ghosh A
J Pharm Pharmacol; 2013 Feb; 65(2):219-29. PubMed ID: 23278689
[TBL] [Abstract][Full Text] [Related]
13. Physical characterization and stability of amorphous indomethacin and ranitidine hydrochloride binary systems prepared by mechanical activation.
Chieng N; Aaltonen J; Saville D; Rades T
Eur J Pharm Biopharm; 2009 Jan; 71(1):47-54. PubMed ID: 18644443
[TBL] [Abstract][Full Text] [Related]
14. Facile formation of co-amorphous atenolol and hydrochlorothiazide mixtures via cryogenic-milling: Enhanced physical stability, dissolution and pharmacokinetic profile.
Moinuddin SM; Ruan S; Huang Y; Gao Q; Shi Q; Cai B; Cai T
Int J Pharm; 2017 Oct; 532(1):393-400. PubMed ID: 28893583
[TBL] [Abstract][Full Text] [Related]
15. Preparation and characterization of simvastatin/hydroxypropyl-beta-cyclodextrin inclusion complex using supercritical antisolvent (SAS) process.
Jun SW; Kim MS; Kim JS; Park HJ; Lee S; Woo JS; Hwang SJ
Eur J Pharm Biopharm; 2007 Jun; 66(3):413-21. PubMed ID: 17240129
[TBL] [Abstract][Full Text] [Related]
16. Characterization, quantification and stability of differently prepared amorphous forms of some oral hypoglycaemic agents.
Chadha R; Bhandari S; Arora P; Chhikara R
Pharm Dev Technol; 2013; 18(2):504-14. PubMed ID: 23061933
[TBL] [Abstract][Full Text] [Related]
17. Dissolution properties of co-amorphous drug-amino acid formulations in buffer and biorelevant media.
Heikkinen AT; DeClerck L; Löbmann K; Grohganz H; Rades T; Laitinen R
Pharmazie; 2015 Jul; 70(7):452-7. PubMed ID: 26373205
[TBL] [Abstract][Full Text] [Related]
18. Amino acids as co-amorphous stabilizers for poorly water-soluble drugs--Part 2: molecular interactions.
Löbmann K; Laitinen R; Strachan C; Rades T; Grohganz H
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):882-8. PubMed ID: 23567485
[TBL] [Abstract][Full Text] [Related]
19. Ternary Eutectic Ezetimibe-Simvastatin-Fenofibrate System and the Physical Stability of Its Amorphous Form.
Knapik-Kowalczuk J; Kramarczyk D; Jurkiewicz K; Chmiel K; Paluch M
Mol Pharm; 2021 Sep; 18(9):3588-3600. PubMed ID: 34420300
[TBL] [Abstract][Full Text] [Related]
20. Coamorphous drug systems: enhanced physical stability and dissolution rate of indomethacin and naproxen.
Löbmann K; Laitinen R; Grohganz H; Gordon KC; Strachan C; Rades T
Mol Pharm; 2011 Oct; 8(5):1919-28. PubMed ID: 21815614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
